Radiopharm Theranostics (Radiopharm Theranostics) Market Cap : $10.13 Mil (As of May. 24, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Radiopharm Theranostics Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Radiopharm Theranostics's share price for the quarter that ended in Dec. 2023 was $0.09. Radiopharm Theranostics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 371.64 Mil. Therefore, Radiopharm Theranostics's market cap for the quarter that ended in Dec. 2023 was $33.45 Mil.

Radiopharm Theranostics's quarterly market cap increased from Dec. 2022 ($0.00 Mil) to Jun. 2023 ($32.33 Mil) and increased from Jun. 2023 ($32.33 Mil) to Dec. 2023 ($33.45 Mil).

Radiopharm Theranostics's annual market cap stayed the same from . 20 ($0.00 Mil) to Jun. 2022 ($0.00 Mil) but then increased from Jun. 2022 ($0.00 Mil) to Jun. 2023 ($32.33 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Radiopharm Theranostics's Enterprise Value for Today is $8.87 Mil.

Radiopharm Theranostics Market Cap Historical Data

The historical data trend for Radiopharm Theranostics's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Radiopharm Theranostics Market Cap Chart

Radiopharm Theranostics Annual Data

Trend

Jun22

Jun23

Market Cap

32.33

Radiopharm Theranostics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23
Market Cap	-	-	-	32.33	33.45

Competitive Comparison of Radiopharm Theranostics's Market Cap

For the Biotechnology subindustry, Radiopharm Theranostics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Radiopharm Theranostics's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Radiopharm Theranostics's Market Cap distribution charts can be found below:

* The bar in red indicates where Radiopharm Theranostics's Market Cap falls into.

Radiopharm Theranostics Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Radiopharm Theranostics's Market Cap for the fiscal year that ended in Jun. 2023 is calculated as

Market Cap (A: Jun. 2023 )	=	Share Price (A: Jun. 2023 )	*	Shares Outstanding (EOP) (A: Jun. 2023 )
	=	$0.09	*	359.265
	=	$32.33

Radiopharm Theranostics's Market Cap for the quarter that ended in Dec. 2023 is calculated as

Market Cap (Q: Dec. 2023 )	=	Share Price (Q: Dec. 2023 )	*	Shares Outstanding (EOP) (Q: Dec. 2023 )
	=	$0.09	*	371.639
	=	$33.45

Radiopharm Theranostics (OTCPK:RDPTF) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.

Radiopharm Theranostics Market Cap Related Terms

Thank you for viewing the detailed overview of Radiopharm Theranostics's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.

Radiopharm Theranostics (Radiopharm Theranostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Radiopharm Theranostics Ltd (OTCPK:RDPTF) » Definitions » Market Cap

Comparable Companies

Traded in Other Exchanges

RAD:Australia

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.radiopharmtheranostics.com

Radiopharm Theranostics Ltd is a Australian based clinical-stage radiotherapeutics company which is targeting cancer. The company has a pipeline of around four licensed platform technologies, with diagnostic and therapeutic applications in both pre-clinical and clinical stages of development. The company is engaged in research, development and commercialisation of health technologies.

Radiopharm Theranostics (Radiopharm Theranostics) Headlines

From GuruFocus

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-30-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 07-10-2022

PIVALATE ACHIEVES POSITIVE PHASE 2 DATA IN BRAIN METS TRIAL

By PRNewswire PRNewswire • 10-19-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-20-2022

RADIOPHARM ENTERS INTO STRATEGIC COLLABORATION WITH LANTHEUS AND ASSUMES PD-L1 LICENSING AGREEMENT FROM NANOMAB

By PRNewswire PRNewswire • 08-04-2022

RAD adds brain tumor technology to portfolio

By PRNewswire PRNewswire • 06-10-2022